1.50 / AMA PRA Category 1 CreditsTM 1.50 / CE for Nurses
Provided by Physicians' Education Resource®, LLC (PER®)
This activity is supported by independent educational grant from Eli Lilly and Biogen. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
Despite the substantial progress made in understanding and treating Alzheimer’s disease in recent years, no disease modifying treatments are currently available such that care has been limited to treatment of dementia symptoms and pursuit of the best possible quality of life. With increased federal funding for research and emerging new treatments, however, the importance of early diagnosis and participation in clinical trials cannot be emphasized enough. During this Medical Crossfire®, expert faculty will engage in a multidisciplinary roundtable discussion that includes a neurologist and a geriatrician with a neuroscience background. A patient advocate and early-stage patient give voice to the many facets of lifestyle management and future planning. This activity provides key guidance for diagnosing and treating Alzheimer’s disease and promoting the collaborative care between primary care providers, geriatricians, neurologists and psychiatrists who not only have the patients’ needs at heart, but include caregivers as a member of the multidisciplinary team, steadfastly involved in decision-making processes.
This educational activity is designed for primary care providers, neurologists, geriatric specialists, and psychiatrists who treat patients with AD. Nurse practitioners, nurses, physician assistants, researchers, and other healthcare professionals interested in the treatment of AD are invited to participate.
After completing this activity, clinicians should be better able to:
Describe neurodegenerative changes that are considered the hallmarks of AD
Describe screening and diagnostic tools for the early identification of individuals with AD
Describe emerging biomarkers for earlier and more accurate diagnosis
Select appropriate therapy for patients with AD to slow disease progression and improve patient and caregiver quality of life (QoL)
Describe lifestyle modifications that can improve QoL for patients and caregivers
Conflict Of Interest Disclosure Policy
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI. Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
Chair/Moderator Richard S. Isaacson, MD Director of the Alzheimer’s Prevention Clinic Weill Cornell Memory Disorders Program Director of the Neurology Residency Training Program Weill Cornell Medical College/New York-Presbyterian Hospital New York, NY
Dr. Isaacson discloses the following: Consultant: 23 and Me, Eli Lilly, Neurotrack
Faculty Howard Fillit, MD Founding Executive Director and Chief Science Officer Alzheimer’s Drug Discovery Foundation Clinical Professor of Geriatric Medicine and Neuroscience The Icahn School of Medicine at Mount Sinai New York, NY
Dr. Fillit discloses the following: Consultant: Axovant Sciences, Eli Lilly, Merck & Co., Otsuka
James Taylor Patient Advocate
Mr. Taylor has no relevant financial relationships with commercial interests to disclose.
Geri Taylor Patient
Ms. Taylor has no relevant financial relationships with commercial interests to disclose.
Accredited Provider Disclosure
The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with commercial interests to disclose.
AMA PRA Category 1 Credit(s)TM
Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
Physicians' Education Resource®, LLC is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 Contact Hour.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any of the companies that provided commercial support for this activity.
In order to receive credit, participants must complete the pre-assessment questions, view the activity in its entirety, and complete the post-test and program evaluation. Participants must also score at least 70% on the post-test. You will receive a digital copy of your credit certificate at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.